Blood Test to Measure DNA Damage in Blood

Gamma-H2AX as a Molecular Predictor of Prostate Cancer Radiosensitivity

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00523471

Enrollment

Registered

2007-08-31

Start date

2007-07-31

Completion date

2010-06-30

Last updated

2016-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

prostate cancer, gamma H2AX, radiosensitivity

Brief summary

To check the radiosensitivity level in individual patients based on their DNA damage level.

Interventions

PROCEDUREBlood test

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Healthy volunteers

Inclusion criteria

* prostate cancer diagnosis * undergoing radiotherapy * agree to participate in study

Exclusion criteria

* not willing to participate * not undergoing radiotherapy

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026